London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
From memory, Dan said even though they're working on NXP004 in the background, he didn't expect there to be substantial news on this one until end of Q2. Well that's only 4 months away now so it soon be here.
Are you an insider then Aim?
Oh! I would not be so sure!! Imo :)
Indeed Moshin, but that's far in the future, they've not even filed its patent yet, NXP001 & 002 will provide near term excitement.
Soup, this bit from Dan Got me excited. ‘NXP004 introduces a strong new candidate to our development pipeline which we believe offers significant commercial potential in multiple therapeutic areas.' https://www.share-talk.com/nuformix-plc-lonnfx-ceo-dr-dan-gooding-interview/#gs.yqf3xt. Also the words Significant & multiple. DYOR
Buy, take a bit of profit on big news and hold the rest for a couple of years when NFX will be sold for many, many, many, many, many and many multiples of today's current share price. Dan has already said they're building the company up to sell it in the near future therefore don't listen to the noise just hold and wait to be highly rewarded.
Mohsin, why are you excited about NXP004? Do you know what it does?
I’m also quite excited about the prospect of NXP004, and what that entails. Although the recent update said it was promising didn’t get much of a follow through as of yet. So hopefully we can get some added info which will take this to another level together with the anticipated licensing.
I clicked through to the link that Aim helpfully provided on the NXP002 patent & was amazed to see its potential uses outside of fibrotic treatment, this caught my eye:
"It has been reported that tranilast has the ability to induce or enhance neurogenesis and, therefore, could be used as an agent to treat neuronal conditions such as .... multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer'"'"'s disease..."
Thanks for taking the time to reply. I was interested to know if you had come across information that gave you that level of certainty other than the podcasts etc. This is now also my largest investment so we're on the same page!
I personally find the re-posting of RNSs useful - they remind me of all the things I have looked at previously but may not have remembered. They also come with a little explanation from Aim4utopia which I also find useful. Plus, some people coming on here may not have done that research and they see it presented for them.
Regarding that one sentence you have decided to pluck out. I was saying it with such comfortableness because Dan said the word progress a couple of times it in his podcast.
He said the raise "allows us to progress NXP002 and NP004 programmes."
Regarding impact of coronavirus, he said: "It's not effecting us at the moment. We're able to progress things...things are going just fine."
"This is a very technical negotiation with exchange of data in both directions but I'm really pleased with where things are. We're working on the best deal for all stakeholders."
'We're working', not were working or have been working but 'we're'. That is the language of progress being made.
Regarding other news. I am not alone on here, in thinking we may and it was the word 'may' I used, receive other news.
A very exciting time ahead for my biggest investment.
Albi thank you for your response.
I have heard so many posters try using that old chestnut against other posters.
When it comes to facts rather than supposition on a Chat Bulletin Board, I think we all know that everything posted here is opinions.
If you would rather facts than supposition then these chat boards really are not the place for people that only interested in such?
The only facts are either Dan and the directors come and speak on here or they shut these chat boards down and you await the red dots.
Otherwise I think your question is an impossibility for anyone here that includes you.
As for other news I very much expect other news also.
Thanks Aim for reposting previous RNS's .
As I have invested my actual money here, yes I have read and done my research.
My question to Hopeabound was on what factual basis did he quote the following:
"We may have other news on other things before NXP002 too - but sure as I have a coffee every morning, progress is being made."
As this made it sound like he was saying he had definitive information that this was actually so rather than supposition. I would rather hear fact than supposition when it comes to my investment.
Another great post Aim, I’m locked into this and keep buying into the dips with glee. It does me the favour of averaging down my price & buying into a great future. It doesn’t matter to me if it’s weeks, months or years. I know what I’m investing into here, that is something that is huge judging by the data and patents. Don’t think a lot of people have a real grasp of what is going on here. Waiting patiently for the BOD to bring it to fruition.
This is The patent filed by Joanne for Nuformix
Click down and read the other uses and findings on this drug. It’s incredible what the large potentials are on the further uses. Like NXP001 NXP002 has many other lines some those being Liver and Kidneys. We hold the patent and proven we have potentially unlocked it. The value is immense.
It takes as long as it takes. Here though with known drug previously approved safety data like CINV on NXP001, Nuformix are dealing with an already approved drug and this is a major drug. It’s not just a simple reprofiling for IP this is significantly improving a hugely commercial drug and reprofiling to the ownership of Nuformix. This has been many years in the making and the original key to values of sale of the Nuformix that were discussed. You can understand why Dan needs to make sure that they get this correct but also why they won’t rush such a monumental decision.
We now have Ebers, NXP001 more valuable lead and NXP004 on top. With other molecules and lines moving. We really only need NXP002 to succeed but we have multiple leads so massively derisking the company as a whole.
Albi looking back at the thread you may have been responding to him stating about Nuformix being resilient in current climate.
If that was your question then my answer to that would be as such.
Nuformix have funds and income from Ebers at some point China excluding the placing which enabled NXP002 and NXP004 to be completed through this year and into 2021.
Of course hopefully more funds will come potentially this year from a deal on NXP002 and whatever else that may get progression.
They have very very small overheads in their Cambridge office with few staff.
They don’t rely on and consumer consumption.
Our testing at current is UK based potentially on new deals this could be taken to other parts of the globe ie Japan?
The news delays have been prior to the current Coronavirus and as such the share took a hammering in value due to the delays so imo nothing is priced in and we are well undervalued as such imo.
We have had joining of some very prominent people including our leading world scientists on IPF and our latest edition to the board which is a massive bonus.
One of the hardest things in the science world is to attract talent due to the massive lack of experienced scientists. So Nuformix has pulled in the heavyweights. That in itself is very telling.
Therefore with news on near horizon potentially whether it’s March April May this is a fantastic company to sit and wait calmly in for delivery. On delivery this will explode guaranteed. We just need delivery obviously. GL ;)
Nuformix Reports Results from Novel Pre-Clinical Trial in IPF for NXP002 Programme
Data show Nuformix Investigational Candidates (NXP002) outperform current standard of care
Cambridge, UK, 3rd December 2018: Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces results from the completion of its innovative pre-clinical trial for its NXP002 fibrosis programme in human idiopathic pulmonary fibrosis ('IPF') against standard of care.
Multi-patient tissue studies were performed in partnership with Newcastle University, UK using a leading-edge human tissue trial model that closely replicates the clinical disease:
· Data demonstrates NXP002 candidates strongly inhibit fibrosis ex-vivo, even in very severely fibrotic patient tissue, giving strong support for treating IPF and other fibrotic lung conditions
· In addition, NXP002 demonstrated specific action measured against key inflammatory targets
· NXP002 out-performed current standard of care treatment, Esbriet ® (pirfenidone)
In partnership with the Newcastle University Fibrosis Research Group, UK, these results are the first of their kind to be published. Despite this being a challenging model of end-stage disease, the outcomes are considered highly positive and a portent for wider applications in other fibrotic lung conditions.
Dr Dan Gooding, CEO, Nuformix plc, said: "Despite the advent of new treatments, life expectancy has not really changed for patients diagnosed with IPF. Few patients respond to current treatments and have to tolerate severe side effects that dramatically impact quality of life - severe vomiting on one therapy or severe diarrhoea on the other. This promising data gives us confidence in our ability to both inhibit fibrosis and attenuate inflammation in patients without these side effects.
"Newcastle University use a highly innovative new human tissue model, which has the potential to become the new gold standard for pre-clinical studies. These findings are important for IPF patients and show our NXP002 programme can play an important role in improving on current treatment options and extending both life and its quality."
Well as anyone who has read the RNS’s on this company and some of us who have been here for few years, it’s based Albi in the results of the Human Lung tissue tests they did in 2018. Using Newcastle university and waiting for the required living human lung donation which is why sometimes it takes a while to get the data understandably. NXP002 version of Tranalist showed not only to beat the current drugs on the market but to actually halt the disease in its tracks.
It’s blooming exciting to have achieved this and to think this year Nuformix are taking it further towards the human testing.
Where you asking Hopebound where he gets his info from Albi? If so it’s in the news release. Obviously one of the main points of the cocrystal product is it makes it far more easily absorbed so to get the same requires effect you only need a tiny amount which inherently means less side effects but also you can have more of the required part of the drug that has a positive effect.
Therefore Nuformix have potentially an patented IPF drug which can be administered using an inhaler that halts IPF. Currently you have less than 3 years to live on prognosis of IPF and you need to be in hospital to have the drug administered I believe. To which patients get terrible side effects and usual give up treatment due to cost and illness from it. To live out their final days.
I can’t wait for our next news on results of NXP002. We should also be due something on NXP004 soon imo.
While I certainly hope what you say is true, what 's the factual basis for your post?
That was another thing of their 2018 data findings that they said: 'gives us confidence in our ability to both inhibit fibrosis and attenuate inflammation in patients without these side effects'. https://nuformix.com/app/uploads/2018/12/NFX-NXP002-IPF-Results-RNS-FINAL.pdf - no wonder they are in advanced talks.
Hopefully NXP002 is a real benefit to patients
OFEV is Nintedanib and apparently has a number of side effect including severe renal impairment and liver impact so not surprising patients stop taking treatments.
General warnings for Nintedanib
Moderate to severe hepatic impairment. Peanut or soya allergy. Pregnancy; ensure hormonal and barrier contraception and continue for =3 months after treatment. Lactation.
Mild hepatic or severe renal impairment (CrCl <30ml/min). Perform LFTs before and during treatment, discontinue permanently if signs of liver injury occur. Monitor renal function esp in patients with risk factors for renal impairment. Predisposition to bleeding. Increased cardiovascular risk; consider treatment interruption if signs of myocardial ischaemia occur. Previous abdominal surgery; do not start treatment for =4 weeks after surgery, discontinue permanently if GI perforation occurs. History of peptic ulceration or diverticular disease. Risk of aneurysm or artery dissection. Monitor BP. Risk of impaired wound healing. Risk factors for QT prolongation.
Thanks Mars1 - it's a wanted product alright. Exciting times. They are smart folk at Nuformix. Choose their drug carefully for how it can be improved and where there is high commercial benefit. As the market collapses in freefall (who knows where the bottom is there), the advanced talks continue, agreed in principle, as data is being gone through diligently. The Japanese pharma company want it and Dr Gooding says he is happy with where things are. We may have other news on other things before NXP002 too - but sure as I have a coffee every morning, progress is being made.
Cost of OFEV
The cost for Ofev oral capsule 100 mg is around $10,955 for a supply of 60 capsules, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans. Ofev is available as a brand name drug only, a generic version is not yet available.
https://www.drugs.com › ... › Ofev
Ofev Prices, Coupons & Patient Assistance Programs - Drugs.com
Hard to believe anyone could drive this price this low if the results of NXP002 are better than current treatments in such a large market. Hope they are progressing clinical tests while we await Japan news.